Louisiana State Employees Retirement System Purchases New Position in Bruker Corporation $BRKR

Louisiana State Employees Retirement System purchased a new stake in Bruker Corporation (NASDAQ:BRKR) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 32,200 shares of the medical research company’s stock, valued at approximately $1,163,000.

Several other hedge funds have also recently bought and sold shares of the stock. Orbis Allan Gray Ltd lifted its holdings in shares of Bruker by 5.4% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after acquiring an additional 761,258 shares during the period. State Street Corp grew its holdings in shares of Bruker by 2.5% in the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after purchasing an additional 91,706 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Sculptor Capital LP increased its position in shares of Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after purchasing an additional 476,363 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Bruker by 2,963.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after purchasing an additional 2,289,269 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Wolfe Research initiated coverage on shares of Bruker in a research report on Monday, June 1st. They issued a “peer perform” rating on the stock. Stifel Nicolaus set a $45.00 target price on shares of Bruker in a research note on Friday, May 8th. UBS Group set a $60.00 target price on Bruker in a report on Wednesday, June 24th. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Finally, Citigroup increased their price target on Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Bruker presently has an average rating of “Hold” and an average target price of $54.54.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $61.64 on Friday. The firm’s 50-day simple moving average is $50.57 and its 200 day simple moving average is $45.02. The company has a market cap of $9.38 billion, a price-to-earnings ratio of -256.83, a price-to-earnings-growth ratio of 1.97 and a beta of 1.29. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $64.54.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, June 22nd. Bruker’s dividend payout ratio is -83.33%.

Insider Activity at Bruker

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 27.20% of the stock is owned by company insiders.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.